Abstract:OBJECTIVE:To develop human papillomavirus (HPV) 16 DNA vaccine for the treatment of HPV16 infection and its related tumors.METHODS:HPV16 oncogene E7 was modified by combined approaches including insertion and replication of specific region of E7 gene, murine codon optimization, and point-mutation at transforming regions of the E7 protein. The resulting artificial gene, named as mE7, was obtained by gene synthesis. The mE7 gene was then genetically fused to murine CD40 ligand (CD40L) by overlapping PCR to form the mE7/CD40L fusion gene. The mE7/CD40L gene was inserted into pVR1012 plasmid and then immunized C57/BL6 mice intramuscularly. The E7-specific IFN-gamma-secreting CD8+ T cells were analyzed with EIISPOT, and E7-specific antibody was measured by indirect ELISA. FACS assays were performed to analyze the activation of E7-specific Th cells. Mice were vaccinated, followed by tumor challenged or challenged before immunization. Tumor growth was observed.RESULTS:The mE7 DNA vaccine elicited an increased E7-specific antibody level (P < 0.01), E7-specific IFN-gamma-secreting CD8+ T (P < 0.01), and CD4+ T cells number (P < 0.05), compared with those of mice immunized with wE7 gene. Furthermore, the mE7/CD40L DNA vaccine elicited an increased number of E7-specific IFN-gamma secreting CD8+ T cell compared with that of mice immunized with mE7 gene (P < 0.01); however, no significant differences were found between mice immunized with the mE7 gene and mE7/CD40L fusion gene in the E7-specific antibody production and Th cell activation. In the preventive experiment, all mice received the mE7 or mE7/CD40L remained tumor-free 7 weeks after challenges with TC-1 tumor cells, while the wE7 group exhibited tumor growth within 2 weeks. In the therapeutic experiment, all the mice in the wE7 group exhibited tumor growth within 8 days, while among mice receiving the mE7 and mE7/CD40L, 30% and 45% of mice remained tumor-free after TC-1 challenge, respectively. HE staining of tumor tissues showed copious lymphocytes infiltration around tumor cells in mE7 and mE7/CD40L mice with regression of tumor growth.CONCLUSIONS:The mE7 DNA vaccine increases the E7-specific humoral and cellular immune responses, and the fusion of CD40L to mE7 gene enhances the specific immune responses and anti-tumor effects against HPV16 E7-expressing murine tumors. mE7/CD40L may therefore be a suitable and promising target for HPV16 therapeutic vaccine.

[Cloning and Expressing of Human Papillomavirus 16 E7C Subgene].

[Cloning of Human Papillomavirus Type 16 E7 Gene and Expression in E. Coli].

Cloning and Expression of HPV 6b E7 Gene

Construction, Expression, Purification and Identification of Chimeric HPV16 E7-L1 Virus Like Particles

Construction of Eukaryotic Expression Fusion Plasmid of HPV6b E7 Gene and CRT Gene

Identification of predicted epitopes of HLA-A * 0201-restricted cytotoxic T lymphocytes derived from human papillomavirus type 11 E7 antigen

Digital RNA Sequencing of Human Epidermal Keratinocytes Carrying Human Papillomavirus Type 16 E7

Construction of Recombinant HPV16 E7 Antigen Vaccinia Virus

Expression of human papillomavirus type16 late gene (L1) in prokaryotic cells and its immune effict observation

[Isolating, Cloning, and Sequencing of HPV16E6E7 Gene from a Cervical Carcinoma Biopsy in Shandong Province].

Expression and Purification of HPV58 E1 Protein and Preparation of Polyclonal Antibodies against HPV 58 E1 Protein

Construction of a Chimeric Gene of Human Papillomavirus Type 16 L1-E7 and Immunogenicity of Expressed Fusion Protein

Mapping of Cytotoxic T Lymphocytes Epitopes in E7 Antigen of Human Papillomavirus Type 11

Transforming Activity of a Novel Mutant of HPV16 E6E7 Fusion Gene

Construction of the Expression Plasmid Paav-Ires-hrgfp Encoding the Human Papillomavirus 16 E6E7

Preparation of a Monoclonal Antibody Against the Human Papillomavirus Type 16 E7 (HPV 16 E7 ) Protein

A Replicative Recombinant HPV16 E7 Expression virus upregulates CD36 in C33A cells

Linkage of Modified Human Papillomavirus Type 16 E7 to CD40 Ligand Enhances Specific CD8 + T-lymphocyte Induction and Anti-tumour Activity of DNA Vaccine

A Novel Mutant of Human Papillomavirus Type 18 E6E7 Fusion Gene and Its Transforming Activity.

Immunohistochemical Detection of Human Papillomavirus 16 E7 Oncoprotein in Cervical Lesions.

Production of Polyclonal Antibody to the HPV58 E7 Protein and Its Detection in Cervical Cancer.